These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1583771)

  • 1. Plasminogen activation system of the platelets.
    Park S
    Rinsho Byori; 1992 Mar; Suppl 92():131-43. PubMed ID: 1583771
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
    Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
    Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress in fibrinolytic mechanism].
    Yasukouchi T
    Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
    [No Abstract]   [Full Text] [Related]  

  • 4. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of venous occlusion on the PAI and antiplasmins release from platelets.
    Woods AI; Nadra CA; Lazzari MA
    Thromb Res; 1989 Nov; 56(3):491-5. PubMed ID: 2515615
    [No Abstract]   [Full Text] [Related]  

  • 8. Urinary tissue type plasminogen activator and plasminogen activator inhibitor in renal transplant patients.
    Ikegami M; Ishii T; Uemura T; Kunikata S; Matsuura T; Akiyama T; Kurita T
    Transplant Proc; 1992 Aug; 24(4):1547-8. PubMed ID: 1496654
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
    Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
    Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
    Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
    Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
    Collen D
    Thromb Haemost; 1980 Jun; 43(2):77-89. PubMed ID: 6450468
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
    Swiercz R; Wolfe JD; Zaher A; Jankun J
    Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and plasminogen activation.
    Loscalzo J; Pasche B; Ouimet H; Freedman JE
    Thromb Haemost; 1995 Jul; 74(1):291-3. PubMed ID: 8578474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
    Krishnamurti C; Alving BM
    Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.